Twist Bioscience Form 4 Filings

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 5,127 shares of Common Stock at an average price of $57.1488 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans and are described as non-discretionary "sell to cover" transactions.

Following this tax-related sale, Leproust directly holds 853,760 shares of Common Stock. She also holds an employee stock option that is exercisable for 64,950 shares of Common Stock at an exercise price of $67.8500 per share, with an expiration date of August 31, 2030.

Twist Bioscience Corp SVP Paula Green reported an open-market sale of 1,116 shares of common stock at $57.1488 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After the transaction, she directly holds 122,988 shares of Twist Bioscience common stock.

Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 2,844 shares of common stock at an average price of $57.1488 per share. The footnote explains these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.

The filing states these “sell to cover” transactions are mandated by the issuer’s plan election and are not discretionary trades by the executive. After this tax-related sale, Finn directly holds 278,964 shares of Twist Bioscience common stock.

Twist Bioscience Corp’s Chief Accounting Officer Robert F. Werner reported a small, mandated share sale tied to equity compensation taxes. On May 4, 2026, he sold 164 shares of common stock at $57.1488 per share to cover tax withholding from vesting Restricted Stock Units.

The company’s equity incentive plan requires these “sell-to-cover” transactions, and the footnote states they are not discretionary trades by Werner. After this tax-related sale, he directly owns 54,635 shares of Twist Bioscience common stock.

Twist Bioscience Corp director Melissa A. Starovasnik sold shares in a planned transaction. On April 27, 2026, she completed an open-market sale of 500 shares of Common Stock at $61.83 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating it was scheduled in advance. After this transaction, she continues to hold 25,222 shares directly.

Twist Bioscience Corp’s President and COO Patrick John Finn reported an open-market sale of 2,321 shares of Common Stock at $60.761 per share. According to the footnote, these shares were sold solely to cover tax withholding triggered by vesting of Restricted Stock Units under the company’s equity plans and were not discretionary trades. After this transaction, he directly holds 281,808 shares of Twist Bioscience common stock.

Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock. She exercised employee stock options to acquire 9,671 shares at an exercise price of $8.82 per share, then sold 9,671 shares in open‑market transactions at prices around $65–66 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions she directly owns 858,887 shares of Common Stock and retains employee stock options, including a grant tied to 64,950 underlying shares with a $67.85 exercise price.

Twist Bioscience Corp Chief Financial Officer Adam Laponis sold 4,000 shares of Common Stock in an open-market transaction. The sale occurred at a price of $60.00 per share on April 17, 2026. After this transaction, he directly holds 118,694 shares of Twist Bioscience common stock.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Laponis previously adopted on May 8, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.

Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported an open-market sale of 3,000 shares of common stock at $55.00 per share. The transaction was made under a previously adopted Rule 10b5-1 trading plan. Following this sale, he continues to hold 122,694 shares directly.

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans, and were not discretionary trades. After this transaction, Laponis directly holds 125,694 shares of Twist Bioscience common stock.

Twist Bioscience director Melissa A. Starovasnik executed an open-market sale of 1,000 shares of Common Stock at $51.00 per share on April 1, 2026. After the transaction, she directly holds 25,722 shares of Twist Bioscience common stock.

The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the transaction was planned in advance rather than timed discretionarily.

Twist Bioscience Corp officer Dennis Cho reported a mandated sale of 354 shares of Common Stock at $43.7864 per share to cover tax withholding on vesting Restricted Stock Units. After this sell-to-cover transaction, Cho directly holds 137,903 Twist Bioscience shares.

Twist Bioscience Corp senior vice president of human resources Paula Green reported a small sale of common stock tied to taxes on vested Restricted Stock Units. She sold 297 shares at an average price of $43.7864 per share through a mandated “sell to cover” transaction under the company’s equity incentive plans. After this tax-related sale, she directly holds 124,104 shares of Twist Bioscience common stock. The footnote explains that the transaction was required to satisfy tax withholding obligations and did not reflect a discretionary trading decision by the executive.

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a small mandated share sale tied to tax withholding. On 2026-03-20, she sold 1,742 shares of common stock at an average price of $43.7864 per share to cover taxes due on vesting restricted stock units, as required under the company’s equity incentive plans and not as a discretionary trade. Following this transaction, she continued to hold 858,887 shares of common stock directly and also held employee stock options, including an award exercisable for 64,950 shares at an exercise price of $67.8500 expiring on 2030-08-31.

Twist Bioscience director Robert Chess exercised stock options for 10,000 shares of Common Stock at $11.89 per share and on the same day sold 10,000 shares at $47.00 per share in an open-market transaction. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. After the sale, he holds 21,084 shares directly and 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.

Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported a small mandated share sale linked to equity compensation. On this Form 4, he disposed of 246 shares of common stock at $46.426 per share on March 6, 2026, and held 54,799 shares afterward.

According to the footnote, the sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity plans. The transaction was executed as a “sell to cover” event and is characterized as non-discretionary rather than an elective open-market trade.

Twist Bioscience Corp officer Dennis Cho reported a small sale of 425 shares of common stock on March 6, 2026 at $46.426 per share. After the transaction, he directly held 138,257 shares. According to the footnote, the shares were sold solely to cover tax withholding on vested restricted stock units and were mandated under the company’s equity incentive plan, so they do not represent a discretionary trade.

Twist Bioscience Corp senior vice president of human resources Paula Green reported an automatic sale of company stock to cover taxes from vesting equity. On March 6, 2026, she sold 935 shares of common stock at $46.426 per share under a mandatory “sell to cover” arrangement. After this tax-related sale, she directly holds 124,401 shares of Twist Bioscience common stock.

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 2,423 shares of common stock on 2026-03-06 at an average price of $46.426 per share. After this transaction, she directly holds 860,629 shares.

According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandated "sell to cover" arrangement, rather than as discretionary trades. She also continues to hold employee stock options, including an award exercisable for 64,950 shares of common stock at an exercise price of $67.8500 per share expiring on 2030-08-31.

Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 4,294 shares of common stock at an average price of $46.7098 per share. The transaction was a mandated “sell to cover” to satisfy tax withholding tied to vesting restricted stock units, not a discretionary trade. After this sale, Finn directly owns 284,129 Twist Bioscience shares, which includes shares acquired through the company’s employee stock purchase plan.

Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported an open-market sale of 1,693 shares of common stock. The transaction occurred on February 23, 2026 at an average price of $46.7098 per share.

According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans, and the sale was not a discretionary trade by the officer. After this sale, Werner directly holds 55,045 shares of Twist Bioscience common stock.

Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience. The shares were sold at a weighted average price of $46.7098 per share to cover tax withholding obligations tied to vesting Restricted Stock Units, under a mandated “sell to cover” arrangement rather than at his discretion.

After this tax-related transaction, Laponis beneficially owns 128,291 shares of common stock, which include shares acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an automatic sale of 7,205 shares of common stock on February 23, 2026 at an average price of $46.7098 per share. The footnotes state this sale was required to cover tax withholding obligations related to vesting restricted stock units under the company’s equity plans and did not represent a discretionary trade. Following this transaction, she directly owned 863,052 common shares. The filing also lists several employee stock option grants and their vesting terms, which remain outstanding holdings rather than new transactions.

Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported an open-market sale of 1,465 shares of common stock at an average price of $46.7098 per share on February 23, 2026. According to the filing, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under the company’s equity incentive plans, and the sale was mandated as a “sell to cover” transaction rather than a discretionary trade. After this tax-related sale, she beneficially owns 125,336 shares, which include shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).

Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share. According to the filing, the shares were sold to cover tax withholding owed on vesting restricted stock units under a mandatory “sell to cover” arrangement, rather than a discretionary trade. After this transaction, Cho directly held 138,682 shares.

Twist Bioscience Corp senior vice president of human resources Paula Green reported an open-market sale of common stock. On February 17, 2026, she sold 39,404 shares at a weighted average price of $52.40 per share, and held 126,041 shares afterward.

Twist Bioscience Corp President and COO Patrick John Finn reported multiple transactions in the company’s stock. On February 17, 2026, he exercised two stock options covering 32,300 and 18,205 shares of common stock.

On the same date, he sold a total of 68,967 shares of common stock in open-market transactions at weighted average prices of $50.321, $51.423, $52.686 and $53.110 per share under a pre-established Rule 10b5-1 trading plan adopted on May 13, 2025. After these transactions, he directly owned 287,788 shares of Twist Bioscience common stock.

Twist Bioscience director Robert Chess reported a small tax-related share sale. On February 13, 2026, 2,184 shares of Twist Bioscience common stock were sold at $48.261 per share to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a prior election rather than a discretionary trade. Following this transaction, Chess directly held 21,084 common shares. He also indirectly held 42,528 common shares through the Chess 1997 Trust, where he and his spouse serve as the sole trustees and beneficiaries.

Twist Bioscience Corp’s President and COO Patrick John Finn reported option exercises and share sales in a pre-planned trading program. On February 12 and 13, 2026, he exercised multiple stock options for common stock at exercise prices of $23.33 and $26.66 per share, converting them into ordinary shares. Over the same two days, he sold 3,500 and 1,750 shares of common stock in open-market transactions at weighted average prices of about $50.225 and $50.041 per share, with individual sale prices ranging from $50.00 to $50.51. All transactions were executed under a Rule 10b5-1 trading plan adopted on May 13, 2025, and he held 306,250 common shares directly after the reported trades, along with remaining vested stock options.

Twist Bioscience chief financial officer Adam Laponis sold 7,000 shares of common stock in an open-market transaction at $50 per share on February 12, 2026. After this planned sale under a previously adopted Rule 10b5-1 trading plan, he directly holds 130,031 shares.

Twist Bioscience Corp executive Dennis Cho reported an open-market sale of company stock. On February 11, 2026, he sold 5,000 shares of common stock at a price of $49.93 per share. After this transaction, he directly owned 138,581 shares.

The filing notes that this sale was carried out under a Rule 10b5-1 trading plan that Cho had previously adopted on May 7, 2025. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, indicating the transaction involves a senior member of management.

Twist Bioscience Corp chief accounting officer Robert F. Werner reported a charitable stock gift. On 02/09/2026, he disposed of 2,000 shares of Twist Bioscience common stock in a bona fide gift to a charitable organization at a reported price of $0 per share.

Following this gift transfer, Werner directly beneficially owned 56,738 shares of Twist Bioscience common stock.

Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share. After this grant, he directly owns 27,571 shares of Twist Bioscience common stock.

These annual award shares will fully vest on the earlier of the one-year anniversary of the grant date or the first annual shareholder meeting after the grant, as long as he continues serving as a non‑employee director. In addition, 76,047 shares are held indirectly through the Keith L. Crandell Trust, for which he and his spouse are co‑trustees and he is the sole beneficiary.

Twist Bioscience director Melissa A. Starovasnik received an annual equity award of 5,095 shares of common stock on February 5, 2026. The shares were granted at a price of $0, increasing her directly held position to 26,722 shares after the transaction.

According to the award terms, 100% of these shares will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as she continues to serve as a non-employee director on the applicable vesting date.

Twist Bioscience director Robert P. Ragusa received an annual stock award of 5,095 common shares on February 5, 2026. The shares were granted at a price of $0 per share, reflecting a typical equity compensation grant for a non-employee director.

According to the vesting terms, 100% of this annual equity award will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as he continues serving as a director. Following this grant, Ragusa beneficially owns 28,983 Twist Bioscience common shares in total, held directly.

Twist Bioscience director Robert Chess reported a stock grant and updated his holdings. On February 5, 2026, he received an annual equity award of 5,095 shares of common stock at a price of $0 per share, increasing his directly held shares to 23,268.

The award vests in full on the earlier of one year from grant or the first stockholder meeting after the grant, so long as he continues as a service provider. He also beneficially owns 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.

Twist Bioscience director Chan Nelson received an annual equity award of 5,095 shares of common stock on February 5, 2026. The award was granted at no cash cost per share and increased Nelson’s directly held stake to 33,251 shares.

The shares vest 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholders’ meeting after the grant, as long as Nelson continues serving as a non-employee director on the applicable vesting date.

Twist Bioscience director Katryn Blake reported a new stock grant. On February 5, 2026, she acquired 5,095 shares of common stock at $0 per share as an annual equity award. Following this grant, she beneficially owns 19,448 common shares, held directly.

The award vests 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholder meeting after the grant, as long as she continues serving as a non-employee director on the applicable vesting date.

Twist Bioscience director Jan Johannessen reported an equity award and related share sale. On 02/05/2026, Johannessen received 5,095 shares of common stock at $0. These annual equity award shares vest in full on the earlier of one year from grant or the first annual stockholder meeting, if he continues as a service provider.

On 02/06/2026, he sold 2,200 shares at $47.9067 per share to cover tax liabilities from restricted stock unit vesting, pursuant to a prior election rather than a discretionary trade. After these transactions, he directly owned 17,754 common shares.

Twist Bioscience Corp's President and COO, Patrick John Finn, reported an automatic sale of common stock tied to equity compensation. On 02/03/2026, 2,705 shares of common stock were sold at $46.576 per share to cover tax withholding obligations from vesting restricted stock units. After this mandated "sell to cover" transaction under the company’s equity incentive plans, Finn beneficially owned 307,788 shares of Twist Bioscience common stock.

Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale. On February 3, 2026, he sold 1,099 shares of Twist Bioscience common stock at $46.576 per share to cover tax withholding from vesting restricted stock units under the company’s equity plans.

After this mandated “sell to cover” transaction, Cho beneficially owned 143,581 shares of common stock in direct ownership. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and the filing notes these were not discretionary trades.

Twist Bioscience Corp’s Chief Executive Officer and director Emily M. Leproust reported an automatic sale of common stock tied to equity compensation. On February 3, 2026, she sold 5,001 shares of common stock at $46.576 per share in a transaction coded “S.”

The filing explains these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, described as a mandatory “sell to cover” and not a discretionary trade. After this sale, Leproust beneficially owned 869,312 shares of Twist Bioscience common stock and continued to hold various employee stock options, including 64,950 performance stock options that vested after meeting performance criteria in December 2022.

Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported mandatory sales of common stock to cover taxes on vested restricted stock units. On February 3, 2026, he sold 175 shares at $46.576 per share. On February 4, 2026, he sold an additional 7,000 shares at a weighted average price of $45.648 per share, with actual sale prices ranging from $45.61 to $45.78. These "sell to cover" transactions were required under the company’s equity incentive plan and are described as non-discretionary. After these transactions, Werner directly owned 58,738 shares of Twist Bioscience common stock.

Twist Bioscience Corporation reported that SVP of Human Resources Paula Green sold 1,194 shares of common stock on February 3, 2026 at $46.576 per share. After this transaction, she directly holds 165,445 shares.

The sale was a mandatory “sell to cover” transaction to satisfy tax withholding owed on vesting restricted stock units, under the company’s equity incentive plan, and was not a discretionary trade by the executive.

Twist Bioscience Corp's President and COO, Patrick John Finn, reported a small mandatory share sale related to equity compensation. On 01/23/2026, he sold 2,390 shares of common stock at $44.908 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and are described as non-discretionary trades. Following this transaction, he beneficially owned 310,493 shares of Twist Bioscience common stock directly.

Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported a planned sale of company stock. On 01/13/2026, he sold 3,000 shares of Twist Bioscience common stock at a price of $40 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he adopted on May 8, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this sale, Laponis directly beneficially owned 137,031 shares of Twist Bioscience common stock.

Twist Bioscience Corp President and COO Patrick John Finn reported an option exercise and share sale in the company’s stock. On January 13, 2026, he exercised a stock option for 3,279 shares of common stock at an exercise price of $8.82 per share and acquired those shares directly.

On the same date, he sold 23,279 shares of Twist Bioscience common stock at a price of $40 per share in an open-market transaction. After these transactions, Finn directly owned 312,883 shares of common stock. The filing notes that these transactions were carried out under a previously adopted Rule 10b5-1 trading plan put in place on May 13, 2025.

Twist Bioscience Corp's Chief Financial Officer, Adam Laponis, reported an automatic sale of common stock to cover taxes related to equity compensation. On January 9, 2026, he sold 2,738 shares of common stock at a price of $35.261 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company's equity incentive plans and were executed as mandatory "sell to cover" transactions rather than discretionary trades. After this sale, Laponis directly beneficially owned 140,031 shares of Twist Bioscience common stock.

Twist Bioscience Corp (TWST) reported an insider transaction by its Senior Vice President, Chief Legal Officer & Corporate Secretary. On 11/21/2025, the reporting person sold 757 shares of Twist Bioscience common stock at a price of $26.5035 per share. After this transaction, the insider beneficially owned 145,402 shares directly.

The company explains that these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The sale was executed under the issuer’s equity incentive plan using a mandated “sell to cover” arrangement, meaning the transaction did not represent a discretionary trade or a change in the insider’s investment view.